Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | PREP | P48147 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | KLK7 | P49862 | 2/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31536535 | 1.00 | MEN1 (0.59) | MEN1KMT2ANPSR1PREPSMN1; SMN2 | |
| SCHEMBL2072827 | 1.00 | MEN1 (0.59) | MEN1KMT2ANPSR1PREPSMN1; SMN2 | |
| SCHEMBL31536575 | 0.90 | MEN1 (0.56) | MEN1KMT2ANPSR1PREPSMN1; SMN2 | |
| SCHEMBL2072837 | 0.88 | NPSR1 (0.54) | MEN1KMT2ANPSR1PREPSMN1; SMN2 | |
| SCHEMBL3148090 | 0.86 | MEN1 (0.51) | MEN1KMT2ANPSR1PREPSMN1; SMN2 | |
| SCHEMBL628051 | 0.86 | MEN1 (0.51) | MEN1KMT2ANPSR1PREPSMN1; SMN2 | |
| SCHEMBL628052 | 0.86 | MEN1 (0.51) | MEN1KMT2ANPSR1PREPSMN1; SMN2 | |
| SCHEMBL1338679 | 0.84 | MEN1 (0.59) | MEN1KMT2ANPSR1PREPSMN1; SMN2 | |
| SCHEMBL29129700 | 0.84 | MEN1 (0.59) | MEN1KMT2ANPSR1PREPSMN1; SMN2 | |
| SCHEMBL29129699 | 0.84 | MEN1 (0.59) | MEN1KMT2ANPSR1PREPSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084467-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| CN-118355020-A | Therapeutic compounds for HIV virus infection | 吉利德科学公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20230331729-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME (NL) | 2023-10-19 | — | — | US | disclosed |
| EP-4249076-A2 | (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-2-METHOXY-N-(PYRIDIN-2-YL)BENZAMIDE AS BTK-INHIBITOR | Merck Sharp & Dohme B.V. (NL) | 2023-09-27 | — | — | EP | disclosed |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-3495368-B1 | (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-2-METHOXY-N-(PYRIDIN-2-YL)BENZAMIDE AS BTK-INHIBITOR | MERCK SHARP & DOHME (NL) | 2023-05-31 | — | — | EP | disclosed |
| EP-3689878-B1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK-INHIBITORS | MERCK SHARP & DOHME (NL) | 2021-10-06 | — | — | EP | disclosed |
| US-20210230166-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2021-07-29 | — | — | US | disclosed |
| US-10934296-B2 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2021-03-02 | — | — | US | disclosed |
| EP-3689878-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK-INHIBITORS | Merck Sharp & Dohme B.V. (NL) | 2020-08-05 | — | — | EP | disclosed |
| US-10239883-B2 | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2019-03-26 | — | — | US | disclosed |
| US-20180179212-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2018-06-28 | — | — | US | disclosed |
| US-9790226-B2 | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as BtK inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2017-10-17 | — | — | US | disclosed |
| US-9758524-B2 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2017-09-12 | — | — | US | disclosed |
| US-20160159810-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2016-06-09 | — | — | US | disclosed |
| US-20160151364-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| US-9290504-B2 | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2016-03-22 | — | — | US | disclosed |
| US-20140155385-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-06-05 | — | — | US | disclosed |
| EP-2734522-A1 | 4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS | Merck Sharp & Dohme B.V. (NL) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013010868-A1 | 4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS | MSD OSS B.V. (NL) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179212-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, SYK, ABL1 | MEN1 3507/4885KMT2A 707/4885NPSR1 4548/4885 |
| US-12084467-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | MEN1 4418/4885KMT2A 3782/4885NPSR1 4454/4885 |
| US-10934296-B2 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | BTK, SYK, ABL1 | MEN1 3507/4885KMT2A 707/4885NPSR1 4548/4885 |
| US-20160159810-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, ABL1, SYK | MEN1 3091/4885KMT2A 575/4885NPSR1 4492/4885 |
| US-20160151364-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, ABL1, SYK | MEN1 3091/4885KMT2A 575/4885NPSR1 4492/4885 |
| US-20210230166-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, SYK, ABL1 | MEN1 3507/4885KMT2A 707/4885NPSR1 4548/4885 |
| US-10239883-B2 | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors | BTK, SYK, ABL1 | MEN1 3507/4885KMT2A 707/4885NPSR1 4548/4885 |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | MEN1 4418/4885KMT2A 3782/4885NPSR1 4454/4885 |
| US-20140155385-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, ABL1, SYK | MEN1 3124/4885KMT2A 528/4885NPSR1 4435/4885 |
| US-20230331729-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, SYK, ABL1 | MEN1 3507/4885KMT2A 707/4885NPSR1 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.